Hackensack, NJ5 Active Studies

Leukemia Clinical Trials in Hackensack, NJ

Find 5 actively recruiting leukemia clinical trials in Hackensack, NJ. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
697
Enrolling

Recruiting Leukemia Studies in Hackensack

RecruitingHackensack, NJNCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

242 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingHackensack, NJNCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

236 participants
Taiho Oncology, Inc.
View Study Details
RecruitingHackensack, NJNCT06384261

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to v...

120 participants
OncoVerity, Inc.
View Study Details
RecruitingHackensack, NJNCT04895436

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

75 participants
AbbVie
View Study Details
RecruitingHackensack, NJNCT04990102

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose ...

24 participants
Georgetown University
View Study Details

About Leukemia Clinical Trials in Hackensack

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 5 leukemia clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 697 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Taiho Oncology, Inc., OncoVerity, Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Hackensack — FAQ

Are there leukemia clinical trials in Hackensack?

Yes, there are 5 leukemia clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 5 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated March 2, 2026 from ClinicalTrials.gov